Apollo Cancer Centres, Navi Mumbai has launched the advanced radionuclide therapy for treatment of thyroid cancer at a symposium held on Saturday, 8th April. The symposium, addressed by various national and international experts, highlighted the latest advancements in the field of thyroid surgery and the role of therapy in offering a precise and targeted approach to cancer treatment for an improved quality of life for cancer patients.
Radionuclide Therapy (RNT) is a new treatment option in the multidisciplinary management of cancer that involves using radiation to target and destroy cancer cells. It is a minimally invasive procedure and is effective in targeting and destroying cancer cells without damaging the surrounding healthy tissue, thus improving outcomes and quality of life for patients. RNT can be used for treating both malignant cancers and some non-cancer conditions.
Dr. Anil D’Cruz, Director of Oncology, Consultant Surgical Oncology Apollo Hospitals, Navi Mumbai, said, “Targeted therapies, such as radionuclide-based therapy is a modern technology that like chemotherapy, reach cells throughout the body by traveling in the bloodstream. However, unlike chemotherapy, the radioactive substances target only diseased cells and thus reduce the potential side effects. By targeting and destroying cancer cells with minimal side effects, it can be an effective treatment for a variety of cancers, including liver cancer, thyroid cancer, prostate cancer and neuroendocrine tumours.
Dr. Anand Zade Head, Department of Nuclear Medicine, Apollo Cancer Centres, Navi Mumbai, said, “The advancements in medical technology have led to a dramatic surge in the development and availability of new cancer treatments. Radionuclide Therapy has emerged as a powerful tool in the fight against cancer that can be delivered in a variety of ways, including through intravenous injection of a radioactive drug, or a radioactive material placed directly in the area of cancer. The radiation is then absorbed by the cancer cells, destroying them.
Mr. Santosh Marathe, Regional CEO – Western Region, Apollo Hospitals, said, “The launch of advanced isotope radionuclide therapy represents a major step forward in the battle against cancer, offering new hope for patients and their families. This cutting-edge treatment will enable patients to receive better care and treatment and will help us to continue to push the boundaries of what is possible in the fight against cancer. Apollo Cancer Care Centres at Navi Mumbai provides all comprehensive treatment modalities at the hospital including organ specific specialists, latest technology including Da Vinci Robotics, rehab services and a very advanced critical care unit. Almost 15% of cancer patients treated at the unit come from peripheral areas of Maharashtra and beyond.”
